Stay up to date with COEUS news and headlines

Stay up to date with COEUS news and headlines

Sep 15, 2022

FROM THE EDITORS: Neil Minkoff, MD, founder of FountainHead HealthCare and the chief medical officer of COEUS Consulting Group, died suddenly on May 4, 2022. Dr Minkoff was a longtime friend of and frequent collaborator with The American Journal of Managed Care® (AJMC®). His colleagues, Joshua Greenblatt, BFA, and Yana Volman, MBA, have worked with the AJMC® editorial team to complete this project: a 2-part series on the future of telehealth. The first part appears online today, and the second part will appear in the October issue of Evidence-Based Oncology™.

The massive pandemic-driven expansion of telehealth will have a consequential, enduring impact on the healthcare delivery system. However, telehealth’s future role in health care delivery is deeply uncertain in terms of its appropriate use across the stages of patient care, among myriad disease types and discrete clinical care needs, and amid uncertainty in payment and provider operational models. [for full article visit]: https://bit.ly/3R3fMaV

Oct 20, 2022

Editor’s Note: This is the second installment of a 2-part series on the rise of telehealth during COVID-19 and its implications. Part I appeared on ajmc.com on September 15, 2022. 

Optimizing telehealth post-COVID-19 will be a balancing act. Despite its meteoric rise during the height of the pandemic, telehealth’s application in complex, chronic, and/or life-threatening conditions may continue to present challenges.1 [to read full article visit]: https://www.ajmc.com/view/the-promise-of-telehealth-a-cautionary-tale

Dr. Hakanson’s Expertise to Advance COEUS’ Medical Affairs and Value-Based Healthcare
Capabilities and Services

DEVON, Pa.–(BUSINESS WIRE)–COEUS Holdings and its subsidiaries (“COEUS”), together a leading health outcomes, contracting, technology, and commercial insights consulting firm, today announced it has appointed Dean Hakanson, MD, to the role of Chief Medical Officer. He joins COEUS following a period of rapid expansion during which the company has experienced double-digit year-over-year growth in both revenue and headcount for the last ten years.

In this role, Dr. Hakanson will drive advancements in COEUS’ expertise and service capabilities for the company’s work in novel, Value-Based Healthcare (VBH) by leveraging real-world data (RWD) to identify areas of opportunity for improving patient health outcomes. Dr. Hakanson’s expertise will be further utilized to develop new Medical Affairs offerings that will assist clients’ clinical and medical staff members in demonstrating their value and contributions toward advancing overall business within biopharmaceutical companies.

“We’re thrilled to have Dr. Hakanson join COEUS as our Chief Medical Officer – a critical position – as we continue our rapid growth,” said Marc Hixson, CEO, at COEUS. “Patient access to innovation is a key part of COEUS’ Medical Affairs’ strategy – a strategy that links to Managed Market’s goal of attaining formulary position through a targeted medical communications strategy that ensures ‘the right patient gets the right therapy at the right time’.”

With a 25+ year distinguished career as an executive in the biopharma industry, Dr. Hakanson’s experience spans work with startups as well as large biotech organizations. Dr. Hakanson has held many leadership positions, including Partner at ZS Associates, CMO at Otonomy, VP and Head of US Medical Affairs at Gilead, and VP of HEOR at Novartis, and has served as an executive leader at BMS, Genentech, and GSK. He is a recognized leader in health policy and economics with past board membership in the National Pharmaceutical Council and the Leonard D. Schaeffer Center for Health Policy and Economics, at the University of Southern California.

“I am eager to drive and contribute to COEUS’ many endeavors as the company continues to transform the model for drug and therapy delivery for its clients,” said Dr. Hakanson. “COEUS is uniquely positioned to enable patient access to innovative medicines – including cell/genetic, oncological, and rare disease therapies – that demand actionable insights and novel solutions for Managed Markets, Value & Access, and Medical Affairs functions. I look forward to contributing to the company’s progress and growth.”

As a board-certified anesthesiologist, Dr. Hakanson’s clinical practice has focused on surgical and ICU patient care. He is recognized across the industry as skilled in creating opportunities and alignment with senior leadership and in developing successful strategic partnerships across the healthcare ecosystem. These partnerships include stakeholders within healthcare payer organizations, organized providers, pharmaceutical manufacturers, and patient advocacy organizations. Dr. Hakanson is a Diplomate of the American Board of Anesthesiology and the American Medical Association and is currently licensed to practice medicine in California.

About COEUS Holdings
The COEUS Holdings teams are singularly driven to optimize market access and commercialization infrastructure for pharmaceutical products. COEUS is a multi-specialty, commercially aligned consultancy, offering a comprehensive suite of informed solutions for successful engagement with organized customers, providers, and patients. Leveraging years of collective real-world market expertise, we offer unique perspectives into clinical and business opportunities to support your brands’ position in the marketplace. COEUS’ mission is to ensure patient access beyond the prescription. We focus on becoming your ally in navigating the healthcare universe. COEUS teams advance thought leadership, technology solutions, and communication initiatives to ensure your brands’ lifelong success. Together, we strive to redefine access solutions in the evolving domestic and global managed care markets. To learn more about COEUS and the company’s offerings, visit www.coeusholdings.com.

Contacts

COEUS Media:
Owen Murphy | 215.680.0155
omurphy@coeusholdings.com

Partnership Will Drive the Adoption of Innovative Payment Models
Needed to Keep Pace with Drug Innovation and High-Priced Therapies

DEVON, Pa. & BLOOMINGTON, Minn.–(BUSINESS WIRE)–COEUS Holdings (COEUS) and its subsidiaries, together a leading value-based healthcare, outcomes contracting and commercial innovation consulting firm, today announced a strategic partnership with Emerging Therapy Solutions® (ETS), a company providing risk management and cost-containment solutions associated with high-cost therapies for rare and complex conditions to healthcare payers, including reinsurers for health plans and stop loss carriers for self-funded employers.

“By partnering with ETS, we can leverage its client network of risk-bearing entities – ranging from first dollar payers to stop loss and reinsurance – for access to these agreements and to continue to pay for these innovative therapies while appropriately adjusting their financial risk or exposure.” Tweet this

“As the pace quickens for the introduction and increased uptake of novel, high-cost treatments, the need to develop and leverage innovative solutions to inform the payor market of what to expect, and accurately track and report patient outcomes after therapy administration continues to heighten,” said David McLean, Chief Executive Officer of ETS. “By providing our payor clients a comprehensive suite of tools and services including our Centers of Excellence (COE) network management, actuarial forecasting tools, leading clinical content, and financial tracking and reporting capabilities, ETS has built relationships with our customers to help support appropriate access for these important life-saving therapies. Through this exciting partnership, ETS is now able to provide access to the value-based contracts utilizing the COEBRA™ Platform for management, allowing us to further enhance our cost-benefit modeling of these new therapies and help our clients adjust their financial exposure over time.”

The partnership will benefit both organizations by combining their innovative services in support of the healthcare industry’s movement towards aligning payments to a therapy’s derived value.

“Innovation in drug development continues to accelerate, providing personalized life-changing therapies to patients in need. That same level of innovation needs to be deployed commercially to ensure that these novel therapies can be paid for within a healthcare system that wasn’t designed to absorb many one-time, high-cost treatments. Long-term success in value-based pricing is contingent not only on accurately defining the right group of patients and analyzing a complete record of their health in order to predict and measure their outcomes, but also ensuring we can trace back payments to any entity that has paid for a given therapy over any number of years so they can recoup some of that cost if the therapy fails” said Marc Hixson, CEO of COEUS. “By partnering with ETS, we can leverage its client network of risk-bearing entities – ranging from first dollar payers to stop loss and reinsurance – for access to these agreements and to continue to pay for these innovative therapies while appropriately adjusting their financial risk or exposure.”

About the COEBRA™ Platform
The COEBRA™ Platform supports the collection and secure housing of data that allows disparate data sources to be combined and analyzed to better demonstrate total therapeutic impact on a patient’s illness. With today’s innovative and breakthrough medicines, there may not always be a clinical marker available to measure the value of the therapy. The COEBRA™ Platform offers a composite view of the therapeutic impact to both payers and manufacturers by incorporating metrics from claims data, electronic medical records, supply chain, patients and providers, and wearables.

About COEUS
The COEUS Holdings teams are singularly driven to optimize market access and commercialization infrastructure for pharmaceutical products. COEUS is a multi-specialty, commercially aligned consultancy, offering a comprehensive suite of informed solutions for successful engagement with organized customers, providers, and patients. Leveraging years of collective real-world market expertise, we offer unique perspectives into clinical and business opportunities to support your brands’ position in the marketplace. COEUS’ mission is to ensure patient access beyond the prescription. We focus on becoming your ally in navigating the healthcare universe. COEUS teams advance thought leadership, technology solutions, and communication initiatives to ensure your brands’ lifelong success. Together, we strive to redefine access solutions in the evolving domestic and global managed care markets. To learn more about COEUS and the company’s offerings, visit www.coeusholdings.com.

About Emerging Therapy Solutions
Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans and self-funded employers manage the risks associated with high-cost therapies for rare and complex conditions. We offer a comprehensive suite of services for solid organ and bone marrow transplants, cell and gene therapies, and other highly specialized therapies. To learn more about ETS and the company’s offerings, visit https://emergingtherapies.com.

Contacts

COEUS Media:
Owen Murphy | 215.680.0155
omurphy@coeusholdings.com

ETS Media:
Sara Hakanson | 612.839.1711
sara.hakanson@emergingtherapies.com

COEUS’ COEBRA™ Platform to Facilitate Value and Outcomes-Based Agreements for Government and Commercial Payers

BOSTON & DEVON, Pa.–(BUSINESS WIRE)–Pear Therapeutics, Inc. (Nasdaq: PEAR) (“Pear”), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced an agreement with COEUS HealthCare, LLC (“COEUS”), a leading life sciences technology and consulting firm, to utilize its outcomes and evidence-based reimbursement adjudication platform, COEBRA™ to help enable value-based contracting. As Pear continues to engage in clinical and contractual conversations with state Medicaid programs, its agreement with COEUS makes it easier for individual states to engage in value-based contracting to access Pear’s PDTs. Pear’s commercial products, reSET® and reSET-O®, are among a limited number of products initially included in the solution and are the only PDTs on the platform.

“We are proud to be the first PDT company to work with COEUS to help streamline value-based contracting with state Medicaid programs,” said Corey McCann, President and CEO of Pear Therapeutics. “States are looking to take innovative approaches to treat patients with mental health conditions like addiction, and we believe COEUS could accelerate our progress with state Medicaid programs by facilitating value-based agreements. States are exposed to both the healthcare and societal costs associated with mental health conditions, and we believe that the value proposition for our prescription digital therapeutics is compelling.”

For several years, Centers for Medicare & Medicaid Services (CMS), has advocated for states to contract with drug and device manufacturers on a metric other than price by linking the cost of the drug/device to the value or outcome it provides.

The agreement between COEUS and Pear could help unlock the potential value that Pear’s PDTs can deliver. Hosting PDTs on the COEUS COEBRATM Platform is intended to provide scalability for Pear across multiple channels including Medicaid, Commercial and other government payers. As part of the agreement, COEUS will provide Pear a turnkey value-based solution that will be made available to most state Medicaid programs. The COEUS COEBRATM Platform will provide a composite view of the real-world therapeutic impact to both the payer and Pear by analyzing metrics from claims data and electronic medical records. The demonstration of total therapeutic impact on a patient’s illness and the resulting system savings are critical to addressing the needs of unique state Medicaid populations.

“Our COEBRA™ platform was created and designed to solve the biggest challenge of managing complex innovative contracts – interpreting detailed, real-time data sets, and accurately summarizing results,” said Marc Hixson, President and CEO of COEUS. “We look forward to working with Pear to streamline the contracting process with state Medicaid programs and help improve patient access to its innovative prescription digital therapeutics.”

reSET Important Safety Information
Indications for Use:
reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is indicated as a 12-week (90-day) prescription-only treatment for patients with substance use disorder (SUD), who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse.

It is intended to:

  • Increase abstinence from a patient’s substances of abuse during treatment, and
  • Increase retention in the outpatient treatment program.

Important Safety Information:
Warnings: reSET is intended for patients whose primary language is English or Spanish with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET is not intended to be used as a stand-alone therapy for substance use disorder (SUD). reSET does not replace care by a licensed medical practitioner and is not intended to reduce the amount of face-to-face clinician time. reSET does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.

Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with substance use disorder also have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should engage in their normal care practices to monitor patients for medical problems and mental health disorders, including risk for harming others and/or themselves.

The long-term benefit of treatment with reSET on abstinence has not been evaluated in studies lasting beyond 12 weeks (90 days) in the SUD population. The ability of reSET to prevent potential relapse after treatment discontinuation has not been studied.

The effectiveness of reSET has not been demonstrated in patients currently reporting opioids as their primary substance of abuse.

This Press Release does not include all the information needed to use reSET safely and effectively. Please see the Clinician Brief Summary for reSET for more information.

reSET-O Important Safety Information

Indications for Use:
reSET-O prescription digital therapeutic is a 12-week (84-day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

Important Safety Information:
Warnings/precautions: reSET-O is intended for patients whose primary language is English or Spanish with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET-O is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET-O to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET-O to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner and is not intended to reduce the frequency or duration of in-person therapy. reSET-O does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.

Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should undertake standard of care to monitor patients for medical problems and mental health disease, including risk for harming others and/or themselves.

The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.

This Press Release does not include all the information needed to use reSET-O safely and effectively. Please see the Clinician Brief Summary Instructions for reSET-O for more information.

About COEUS HealthCare
Established in 2019, COEUS HealthCare is the division of COEUS Holdings responsible for the development of the SaaS solution, COEBRA™, a value-based, outcomes and warranty adjudication platform. COEBRA™ supports the collection and secure housing of data that allows disparate data sources to be combined and analyzed to better demonstrate total therapeutic impact on a patient’s illness. With today’s innovative and breakthrough medicines, there may not always be a clinical marker available to measure the value of the therapy. The COEBRA™ platform offers a composite view of the therapeutic impact to both payers and manufacturers by incorporating metrics from claims data, electronic medical records, supply chain, patients and providers and wearables. For more information, visit www.coeus-healthcare.com.

About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

Forward-Looking Statements from Pear Therapeutics
This press release contains forward-looking statements within the meaning of the federal securities laws that are subject to risks and uncertainties and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally relate to future events involving, or future performance of, Pear. For example, whether Pear’s agreement with COEUS will facilitate, streamline, accelerate the progress of, or make it easier for state Medicaid programs to engage in value based contracting for Pear’s PDTs, whether Pear’s agreement with COEUS will help improve patient access to PDTs or unlock the value of Pear’s PDTs, and whether the value proposition for Pear’s PDTs is compelling, whether having Pear’s PDTS hosted on COEUS’ platform provides scalability for Pear across multiple channels including Medicaid, Commercial and other government payers, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “can”, “should”, “could”, “might”, “plan”, “possible”, “strive”, “aim”, “expect”, “intend”, “will”, “estimate”, “believe”, “predict”, “potential”, or “continue”, or the negatives of these terms or variations of them or similar terminology.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Pear and its management are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i), the rate at which customers integrate Pear’s PDTs into their treatment paradigms, (ii) changes in applicable laws or regulations; (iii) the possibility that Pear may be adversely affected by other economic, business, regulatory, and/or competitive factors; (iv) the evolution of the markets in which Pear competes; (v) the ability of Pear to defend its intellectual property and satisfy regulatory requirements; (vi) the impact of the COVID-19 pandemic on Pear’s business; and (vii) other risks and uncertainties set forth in Pear’s filings with the SEC (including those described in the Risk Factors section). These filings will identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, which are based only on information currently available to us and speak only as of the date of this release. Pear assumes no obligation to publicly update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. Pear gives no assurance that Pear will achieve its expectations.

Contacts

Pear Therapeutics
Meara Murphy
Senior Director, Corporate Communications
meara.murphy@peartherapeutics.com

COEUS HealthCare
Owen Murphy
SVP, Marketing
215.680.0155
omurphy@coeusholdings.com

FRISCO, Texas–(BUSINESS WIRE)–Magellan Rx Management, the full-service pharmacy benefit management division of Magellan Health, Inc., today announced a collaboration with COEUS HealthCare that will support the accelerated adoption of outcomes-based care and help improve patient access to lifesaving therapies, linking health outcomes to the cost of a drug and the value it provides on behalf of Magellan Rx’s state government programs.

“With the publication of the Value-Based Purchasing (VBP) final rule by CMS, state Medicaid programs, commercial payers and manufacturers are set to benefit from changes in best price reporting on utilization associated with outcomes-based contracting” Tweet this

Through this collaboration, Magellan Rx will leverage COEUS HealthCare to develop and administer VBCs on the COEBRA™ Platform, a SaaS solution designed to address the challenges associated with managing outcomes-based agreements. Data, analytics and consensus are common barriers to the implementation of value-based agreements. The COEBRA™ Platform interprets large, disparate, real-world data sets and accurately summarizes results. The demonstration of total therapeutic impact on a patient’s illness and the resulting system savings are critical to addressing the needs of unique state Medicaid populations.

“At Magellan Rx, we are deeply committed to innovation that supports the complex and evolving needs of our customers and the patients we serve. This collaboration brings the best of Magellan Rx’s Medicaid expertise coupled with COEUS HealthCare and the COEBRA™ Platform which will ultimately deliver better health outcomes for patients while also driving positive economic impact on state budgets,” said Meredith Delk, General Manager and Senior Vice President, Government Markets, Magellan Rx Management. “With spending on specialty drugs in Medicaid rising year over year coupled with far more costly drugs coming to market, we must establish new, measurable ways to lower costs and improve patient care. We offer more than 40 years of Medicaid focused expertise, including extensive knowledge of the trends driving state pharmacy spend. By leveraging the COEBRA™ platform, we can further advance the adoption and management of value-based care on behalf of our government and state clients.”

With this collaboration, Magellan Rx will offer MRx Value Plus, a value-based contracting product that provides state Medicaid programs across the country with another tool to manage overall healthcare costs and quality by paying for drugs that are efficacious. MRx Value Plus centers around improving patient care by linking outcomes with cost effectiveness. If health outcomes are not realized, the manufacturer will refund a portion of the cost of the drug back to the state, shifting the focus from volume to value.

“With the publication of the Value-Based Purchasing (VBP) final rule by CMS, state Medicaid programs, commercial payers and manufacturers are set to benefit from changes in best price reporting on utilization associated with outcomes-based contracting,” said Doug Brown, Senior Vice President, Value and Access at COEUS. “What’s really exciting for states is their ability to augment existing volume-based payment methodologies in a way that better aligns drug coverage and reimbursement with validated clinical outcomes. As the pipeline of gene and cell therapy drugs grows, new ways of paying for them are emerging and will become critical for their successful adoption and appropriate use within the patient populations they are designed to help.”

Launched with its first client in 2019, the HIPAA compliant COEBRA™ Platform intakes pharmacy claims, medical claims, invoice data, and patient-reported outcomes into a multi-variable analytical intelligence platform powered to showcase any VBC outcome. Once collected and analyzed, outcomes-based contract metrics determine how the therapy performs in the real world in order to demonstrate effectiveness and support market value with payers, plans, PBMs and, most importantly, the patients they serve.

About COEUS HealthCare:Established in 2019, COEUS HealthCare is the division of COEUS Holdings responsible for the development of the SaaS solution, COEBRA™, a value-based, outcomes and warranty adjudication platform. COEBRA™ supports the collection and secure housing of data that allows disparate data sources to be combined and analyzed to better demonstrate total therapeutic impact on a patient’s illness. With today’s innovative and breakthrough medicines, there may not always be a clinical marker available to measure the value of the therapy. The COEBRA™ platform offers a composite view of the therapeutic impact to both payers and manufacturers by incorporating metrics from claims data, electronic medical records, supply chain, patients and providers and wearables. For more information, visit www.coeus-healthcare.com.

About Magellan Rx ManagementMagellan Rx Management, a division of Magellan Health, Inc., is shaping the future of pharmacy. As a next-generation pharmacy organization, we deliver meaningful solutions to the people we serve. As pioneers in specialty drug management, industry leaders in Medicaid pharmacy programs and disruptors in pharmacy benefit management, we partner with our customers and members to deliver a best-in-class healthcare experience.

About Magellan Health:Magellan Health, Inc. is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare. Magellan supports innovative ways of accessing better health through technology, while remaining focused on the critical personal relationships that are necessary to achieve a healthy, vibrant life. Magellan’s customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. For more information, visit MagellanHealth.com.

(MGLN-GEN)

Contacts

Media Contact: Lilly Ackley, ackleyl@magellanhealth.com, (860) 507-1923

FOR IMMEDIATE RELEASE

MEDIA CONTACT: Owen Murphy
215.680.0155
omurphy@coeusholdings.com

Mirador Global LP and e-Projection formally partner to Further Enhance the Global Reach and Depth of Services Offered by Both Companies

Philadelphia, PA, USA – May 20, 2022 – Mirador Global, LP and e-Projection K.K. speciality consultancies based in Philadelphia, PA, USA and Tokyo, Japan, respectively, today announced a partnership to develop expanded outreach to mutual markets. The partnership will allow both parties to promote businesses to geographies previously unreached, and to mutually share each party’s robust capabilities. Specifically, the partnership gives each company entrée into the other’s country affording both companies the opportunity to bring new business into Japan, the worlds’ 3rd largest market for pharmaceuticals.  Additionally, e-Projection will be able to deliver its insights and services to previously untapped markets by augmenting the needs of Mirador clients.

Mirador helps biopharmaceutical companies develop robust and integrated global commercialization strategies. The company brings extensive consulting expertise to global drug commercialization and market access efforts.

e-Projection is a Tokyo-based consulting firm that helps companies and institutions, namely in the pharmaceutical and biotechnology industries, enter the Japanese market with their products and technologies.

Through this partnership, e-Projection will be able to promote its business to North America and the EU, and Mirador will be able to do so to Japan. Both parties will engage in joint activities to serve their clients in a truly global context, including global research projects and global sales forecasting models.

“We are excited by this opportunity to partner with e-Projection Japan to gain access to their deep experience and expertise in this critical market, stated Lizzie Grosset, Vice President Global Access Strategy, Mirador Global LP. “The partnership enables Mirador us to provide truly global strategic consulting service to its clients. In turn, we look forward to collaborating with e-Projection’s talented team to support the generation of clear, robust US and EU insights-based strategies for their Japanese client base.”

“We have been impressed by the skills and capabilities of the experts at Mirador in the last few years and are thrilled to formalize our partnership with this great company,” said Tosh Nagate, CEO at e-Projection. “With this collaboration, we will develop global insights and strategies that are penetrating and actionable to our Japanese customer base and, at the same time, help the biotech community across the globe with cutting edge findings from the Japanese market.”

About e-Projection

e-Projection is a Tokyo-based consulting firm dedicated to global biotech, pharma, investors, and academic institutions who are interested in bringing their products/technologies to the Japanese market. e-Projection is a one-stop-shop consultancy which covers all the necessary factors for a non-Japanese biotech/pharmaceutical to plan to enter the Japanese market. To learn more about e-Projection, visit http://e-projection.com/

Hixson Was Recognized in the Transformational Leader Category

DEVON, PA – 5.17.22 [AF1] – COEUS Holdings and its subsidiaries, together a leading health outcomes, contracting, technology and commercial insights consulting firm, is pleased to announce that its President & CEO, Marc Hixson, has been named a recipient of a 2022 PM360 Elite 100 Award. PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, has named Hixson as one of the 2022 PM360 ELITE 100 in the Transformational Leader category. Now in its eighth year, the PM360 ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represent the most influential people in the healthcare industry today. 

Since COEUS’ inception in 2009 there has been an emphasis on building service offerings and technologies to help drive the healthcare industry in a more sustainable and financially appropriate direction. Marc’s vision and clear understanding of where the healthcare industry and regulatory bodies are headed has catapulted COEUS and its now five integrated business units into double-digit revenue growth year-over-year for the last decade.

“It’s an honor to be named a Transformational Leader by PM360 for their ELITE 100 Awards,” stated Marc Hixson, President and CEO, COEUS Holdings. “Each year PM360 does a stellar job of recognizing industry leaders in a variety of categories so I’m in good company. I’m looking forward to attending the event and meeting the other recipients and the many people who are committed to advancing patient access to innovative, lifesaving therapies.”

The PM360 ELITE Awards were established in 2015 to recognize individuals and teams who have made a significant impact on the life sciences and healthcare industries throughout their careers. More than 500 submissions were received, and nominees were evaluated and selected by the PM360 editorial staff based on their accomplishments; testimonials from their bosses, clients, and colleagues; and supporting evidence that reflects the impact of their efforts. A total of 100 winners were selected across 20 categories, including Creative Directors, Data Miners, Digital Crusaders, Disrupters, Drug Researchers and Developers, Entrepreneurs, Environmental Champions, Launch Experts, Leaders of the Future, Marketing Teams, Master Educators, Mentors, Patient Advocates, Philanthropic Heroes, PR Gurus, Sales MVPs, Strategists, Talent Acquisition Leaders, Tech-know Geeks, and Transformational Leaders.

“Our industry accomplished great things during the pandemic to ensure people could be protected against COVID, treated for it, and still access all of the other medications they need, but this disruption to our world also revealed ways in which our industry could be even better,” says Anna Stashower, CEO and Publisher of PM360. “Many of this year’s winners sprang into action to improve areas the pandemic exposed as needing changes, including addressing health equity, social determinants of health, clinical research, patient access and affordability, and much more. That’s what makes them the most influential people our industry has to offer—their ability to push the industry forward to make healthcare better for all.”

The winners were profiled in PM360’s May 2022 issue. You can read their profiles online at https://www.pm360online.com/the-2022-pm360-elite-100.   

Additionally, the 2022 ELITE 100 will be celebrated at the annual ELITE Awards Event, which will be held at 230 FIFTH in New York City on July 13th starting at 7 PM EST. A special keynote address from Uber ELITE Winner Mikael Dolsten, MD, PhD, Chief Scientific Officer and President, Worldwide Research, Development, and Medical, Pfizer Inc., will kick off the celebration.

Tickets for the event can be purchased at https://www.pm360online.com/elitetickets.

#  #  #

About PM360

PM360 is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment.

The journal’s targeted and insightful editorial focuses on issues that directly impact critical decision making, including planning and implementation of cutting-edge strategies, trends, the latest technological advances, branding/marketing, advertising/promotion, patient/professional education, sales, market research, PR, and leadership. Additionally, the “360” in the title signifies the span of this critical, how-to info with personal and career insights for an enjoyable and thought-provoking read.

By providing the full circle of enriching content, PM360 is truly an indispensable tool for busy and productive marketing professionals to stay at the top of their game.

About COEUS Holdings
The COEUS Holdings teams are singularly driven to optimize market access and commercialization infrastructure for pharmaceutical products. COEUS is a multi-specialty, commercially aligned consultancy, offering a comprehensive suite of informed solutions for successful engagement with organized customers, providers, and patients. Leveraging years of collective real-world market expertise, we offer unique perspectives into clinical and business opportunities to support your brands’ position in the marketplace. COEUS’ mission is to ensure patient access beyond the prescription. We focus on becoming your ally in navigating the healthcare universe. COEUS teams advance thought leadership, technology solutions, and communication initiatives to ensure your brands’ lifelong success. Together, we strive to redefine access solutions in the evolving domestic and global managed care markets. To learn more about COEUS and the company’s offerings, visit www.coeusholdings.com.


 [AF1]Owen, date correct?

This Appointment Will Further Expand the Company’s Thought Leadership and Continue to Support the Healthcare Industry’s Movement Towards Value-Based Care

September 21, 2021 – Devon, PA – COEUS Consulting Group, a wholly owned subsidiary of COEUS Holdings and together a leading health outcomes, contracting, technology and commercial insights consulting firm, today announced it has hired Matthew Paul as Senior Vice President, Value & Access. Mr. Paul joins the COEUS team after a successful career within senior leadership in the healthcare reinsurance industry most recently at Skyward Accident & Health, formerly known as Houston International Insurance Group (HIIG).

As Senior Vice President, Value & Access, Matt will be responsible for educating pharma/biotech clients on how the reinsurance market may impact their therapy’s utilization, developing actionable strategies on mitigating risk and building technology solutions that remove barriers to access. In addition, Matt will be responsible for building a new service line and solutions geared towards reinsurers themselves to better reduce their risk and exposure in the market.

“COEUS has worked long and hard to build its reputation as a leader in the market in tying health outcomes together with value-based care delivery in an effort to manage drug spend and ensure that appropriate patients receive the therapies they need,” said Marc Hixson, CEO of COEUS Holdings. “Matt’s reinsurance experience in a sector of the market that isn’t clearly understood by employers, manufacturers, and patients will bring tremendous value to all of our clients as they continue to innovate and pay for drugs.”

Prior to Joining COEUS, while at Skyward, Matt had oversight of the A&H Medical Stop Loss division where he worked closely with producers and internal regional underwriting teams to navigate best pricing and condition setting for their mutual clients. Over the past few years, the business model has changed from providing a rate driven product to being consultative, creative, and collaborative due to the emergence of high-cost drugs and therapies that are simply too expensive for the underlying plan to absorb.

“Over the years I have watched as innovative drugs and treatments have come to market while also watched as insurers and self-funded employers figure out how to pay for them. The market is now at a tipping point. In order to continue to see the innovation in drug development, we have to do a better job at figuring out innovative ways to show their value for the cost they carry,” said Mr. Paul, “without that value, innovation will cease, and many diseases will never see a cure. The COEUS team shares that same passion and drive and I look forward to helping be a part of that solution.”

About COEUS Consulting Group
Founded in 2009, COEUS Consulting Group is a boutique life sciences market access strategy consulting firm offering clients commercial support across the entire development spectrum. Our core focus is on delivering thoughtful insight and recommendations for our clients, and we accomplish that by utilizing a unique team of industry experts specific to each client’s needs in conjunction with a broad network of partners and advisors. The Market Access practice works with clients to develop their managed care and pricing and contracting strategy, market access insight generation, HEOR strategy and tactics, launch readiness, account management, operational support, patient access, distribution, and trade and advocacy/policy work. To learn more about COEUS and the company’s offerings, visit www.coeusconsultinggroup.com.

About COEUS Holdings
The COEUS Holdings teams are singularly driven to optimize market access and commercialization infrastructure for pharmaceutical products. COEUS is a multi-specialty, commercially aligned consultancy, offering a comprehensive suite of informed solutions for successful engagement with organized customers, providers, and patients. Leveraging years of collective real-world market expertise, we offer unique perspectives into clinical and business opportunities to support your brands’ position in the marketplace. COEUS’ mission is to ensure patient access beyond the prescription. We focus on becoming your ally in navigating the healthcare universe. COEUS teams advance thought leadership, technology solutions, and communication initiatives to ensure your brands’ lifelong success. Together, we strive to redefine access solutions in the evolving domestic and global managed care markets. To learn more about COEUS and the company’s offerings, visit www.coeusholdings.com.
COEUS Media Contact:
Owen Murphy | 215.680.0155
owen@hyperclearcommunications.com

Acquisition Advances COEUS Solution’s Scalability and Capacity, Providing Clients a More
Robust Set of Offerings

September 21, 2021 – Devon, PA – As COEUS Holdings continues to drive its overall strategic growth plan of ensuring patients have appropriate access to innovative therapies when they need them, the access-focused firm has acquired Afore, a NJ-based customer-centric life sciences consulting firm that focuses on delivering commercial technology solutions and support.

The acquisition enables COEUS to augment and enhance its existing technology capabilities and, in many cases, provide a variety of new services to its client base. Among the services the combined entity will offer include commercial roadmap consulting, software integration services, data integration services, data warehousing and business intelligence solutions, training, and more.

“Today, pharmaceutical manufacturers spend a lot of time, money, and resources trying to understand, select, and implement the right systems, which requires a forward-thinking technology partner to make informed and forward-looking technology decisions,” said Marc Hixson, President & CEO of COEUS Holdings. “Afore’s team of experts specializes in providing clients with that evaluation, implementation and support services and has been independently ranked as the top technology partner by companies such as Veeva, TGaS Advisors and MediSpend. By incorporating Afore into the COEUS Solutions business, COEUS will strengthen its existing commercial technology enablement offerings related to information management, customer relationship management, and regulated content management and add a wealth of new consulting services.”

James Corbett, former pharmaceutical company senior executive and founder of Afore, will serve as
COEUS Solutions Chief Operations Officer. In this role, he will work to enhance the company’s go-to-market strategy, while ensuring that the team is structured appropriately, and client needs are being met.

“The team at Afore is excited to be joining the COEUS Solutions family during a time of exponential growth within the organization,” stated Corbett. “We look forward to contributing our knowledge and experience towards COEUS’ future as the synergies between the organizations–including client support, implementation services, and unique product offerings–will enable us to reach more clients and provide solutions leading to the optimal outcomes they need and expect.”

“The pace of innovation in healthcare requires cutting-edge technologies to optimize patient access to those products as they come to market,” said Mike Zubey, Chief Business Officer of COEUS Solutions. “This is another step in making COEUS Holdings an elite transformation partner for emerging biotech and large Pharma alike. In addition, Afore’s ranking as the top Veeva and Information Management partner to emerging biotech’s is directly in line with our overall strategy. With the technological insights of James and his team, COEUS Solutions has now significantly broadened its offering ensuring that clients will get where they need to go faster and in more scalable fashion.”

Corbett will work directly with Zubey to ensure that COEUS clients are well-informed on the various technology solutions available to them, and which can be best tailored to their specific needs and desired outcomes. Along with the rest of the COEUS leadership team, the two will work to continue to deliver technology and consulting solutions for their clients to ensure patients get access to the therapies they require and deserve.

About COEUS Holdings
The COEUS Holdings teams are singularly driven to optimize market access and commercialization infrastructure for pharmaceutical products. COEUS is a multi-specialty, commercially aligned consultancy, offering a comprehensive suite of informed solutions for successful engagement with organized customers, providers, and patients. Leveraging years of collective real-world market expertise, we offer unique perspectives into clinical and business opportunities to support your brands’ position in the marketplace. COEUS’ mission is to ensure patient access beyond the prescription. We focus on becoming your ally in navigating the healthcare universe. COEUS teams advance thought leadership, technology solutions, and communication initiatives to ensure your brands’ lifelong success. Together, we strive to redefine access solutions in the evolving domestic and global managed care markets. To learn more about COEUS and the company’s offerings, visit www.coeusholdings.com.

About COEUS Solutions
COEUS Solutions provides its clients IT strategy consulting, technology implementation, and integration services along with managed technology and functional services. This ensures that COEUS customers are properly prepared to commercialize and have technology and procedural solutions in place to safeguard success – not only at product launch, but in a sustainable fashion.

COEUS Media Contact:
Owen Murphy | 215.680.0155
owen@hyperclearcommunications.com